在晚期卵巢癌中接受贝瓦西祖马布维持治疗的有效性
Qing Han1, Aiqin He1, Haibo Xu1
1Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China.
African journal of reproductive health
|July 29, 2025
概括
贝瓦西祖马布维护疗法通过提高无进展生存率和整体生存率,显著改善了晚期卵巢癌的结果. 这种治疗还降低了JAK2 / STAT3 / VEGFA通路的调节,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚期卵巢癌带来了重大的治疗挑战.
- 雅努斯激酶2 (JAK2) /信号转换器和转录3的激活器 (STAT3) /血管内皮生长因子A (VEGFA) 途径与卵巢癌的进展有关.
研究的目的:
- 评估贝瓦西祖马布维护治疗在晚期卵巢癌中的疗效.
- 评估贝瓦齐祖马布对JAK2/STAT3/VEGFA通路的影响.
主要方法:
- 一项随机研究涉及126名患有晚期卵巢癌的患者.
- 标准治疗 (化疗,手术) 与标准治疗加上贝瓦齐祖马布维持治疗的比较.
- 对疾病控制率,客观反应率,无进展生存率和整体生存率的分析.
- 对JAK2,STAT3和VEGFA表达水平的评估.
主要成果:
- 贝瓦西祖马布维持治疗显著改善了疾病控制率 (43.75%vs24.19%) 和客观反应率 (76.56%vs48.39%).
- 贝瓦西祖马布组显示显著延长了无进展生存时间 (16.08个月 vs 12.08个月) 和整体生存时间 (30.45个月 vs 22.92个月).
- 贝瓦西祖马布治疗导致JAK2,STAT3和VEGFA的表达减少.
结论:
- 贝瓦西祖马布维护疗法在晚期卵巢癌中是安全有效的.
- 这种疗法显著提高了无进展和整体存活率.
- 贝瓦西祖马布会影响JAK2/STAT3/VEGFA通路,从而促进其治疗效果.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K


